An impulse paper of a green splinter group has ignited a storm in the water glass. Like industry and science lobbyists, the renegades are calling for changes to the EU’s legal GMO framework.

BioProfile FLEX2 combines Nova’s groundbreaking MicroSensor Card technology with optical measurement and freezing point osmometry for an automated and comprehensive cell culture analyzer that eliminates chemistry sensor maintenance, increases analyzer speed, and reduces sample volume.

BIOFLOAT coatings from faCellitate provide a highly defined, fully inert cell- and protein-repellent surface.

Viennese APEIRON Biologics AG raised €17.5m to expand ongoing Phase II trials of its
coronavirus-specific drug candidate APN01 in Europe to the US and Russia. The recombinant angiotensin-converting enzyme 2 (rhACE2) mimics the receptor on the human cells that coronaviruses are using to infect these cell. Preclinical and clinical data demonstrate that APN01 is well-tolerated and can stop the overshooting host immune responses that are triggered by virus proliferation.

If reopening the economy after the prolonged shutdown was the end of the beginning, then the successful development of vaccines and therapeutic antibodies has the potential to be the beginning of the end.

In a Public England Health study, Siemens Healthineers’ COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.

After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).

Leiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push clinical development of VMX-C001, a venom-based modified recombinant Factor X.

Richard Sachse started at the beginning of July as new Chief Medical Officer at Sotio a.s.

A challenge whose success lies in efficient process management and digital development! The times of digitalisation and Industry 4.0 do not stop at the production of medical cannabis for the pharmaceutical industry. The combination of IT systems and blockchain-based processes allows the value-added chain to be automated and the data generated to be mapped in a tamper-proof manner.